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Summary.-A total of 107 patients with bronchial carcinoma have been studied
for the presence of potential circulating tumour markers which might be used
as indicators of recurrence after primary treatment. Plasma carcinoembryonic
antigen (CEA) levels were estimated in every patient and, after a preliminary hor-
mone screening study, plasma calcitonin (CT) and parathyroid hormone (PTH)
levels were assayed in 66 patients. Oat-cell tumours proved to be of particular
interest in that CEA levels > 40 ,ug/l were measured (initially or subsequently) in
40.6% and CT levels were elevated in 75%0. Longitudinal studies point towards the
possible use of elevated marker levels as guides to therapy when all other features
of recurrent disease are lacking. It is clear that no ideal tumour marker exists for
bronchial carcinoma but in an individual case an abnormal level of one or more
marker substances may provide a valuable aid to treatment.
SUCCESSFUL therapy in malignant dis-
ease depends on a correct initial assess-
ment of the extent of spread and then
on appropriate treatment to eradicate all
the tumour tissue. Treatment may pro-
duce a complete remission of symptoms,
yet in many cases there is residual tumour,
either at the primary site or disseminated
widely throughout the body. The ability
to detect such tumour masses and suitable
means to monitor the progress of treat-
ment are necessary prerequisites for
logical therapy.
In cases of bronchial carcinoma (as
in many other types of cancer) the
malignant cells are located in solid
masses forming the primary tumour, or
in discrete lymph node or haematogenous
metastases, and in addition there may
be widely disseminated micrometastases.
The large masses maybe located by clinical
examination or by radiological or isotopic
investigations. But the micrometastases
can only be detected if they produce
substances which can be measured in the
peripheral circulation; so-called "tumour
markers".
Some of these tumour products are
detectable by biochemical methods, and
their presence in the plasma may indicate
persistence of micrometastases after treat-
ment of the overt tumour masses. The
value of such markers can only be deter-
mined by measuring the plasma levels
before and during treatment of the local
disease and during subsequent follow-up.
In choriocarcinoma HCG is a specific
and almost ideal biochemical marker,
whose measurement has led to great
advances in treatment of the disease
(Bagshawe, 1967). No ideal marker exists
for bronchial carcinoma, but a number
of substances have been noted in associa-
tion with these tumours which may
prove useful in planning a therapeutic
approach.
Finding a suitable marker is of the
utmost importance in an individual case
where systemic treatment of micrometa-
stases is contemplated. Particular valueBIOCHEMICAL MARKERS IN BRONCHIAL CARCINOMA
of such an approach can be anticipated
in cases of oat-cell carcinoma, as these
tumours are almost always disseminated
at the time of presentation. There is,
however, evidence to suggest that the
prognosis maybe improved bydestruction
of the main tumour masses by radio-
therapy, and chemotherapy for presumed
micrometastases (Horwitz et al., 1965;
Eagan et al., 1974; Johnson, Brereton
and Kent, 1976). In this study we have
looked at a variety of potential tumour
markers for bronchial carcinoma and the
results would seem to indicate that
carcinoembryonic antigen (CEA) and cal-
citonin (CT) show promise as marker
substances, particularly in the manage-
ment of oat-cell tumours.
MATERIALS AND METHODS
In this study, the number ofinvestigations
carried out on an individual patient has
varied from a single estimation of one or
more potential tumour markers to a series
of estimations before, during and after
treatment. The first marker investigated
was carcinoembryonic antigen (CEA) which
was measured by radioimmunoassay (using
the technique described by Laurence et al.,
1972) in a total of 107 patients.
Later in the study, a pilot group of 12
patients was screened for the presence of
the following hormones: vasoactive intestinal
peptide (VIP), gastric inhibitory peptide
(GIP) and glucagon (Dr S. R. Bloom's
laboratory) FSH, TSH, LH, growth hormone,
prolactin and insulin (Dr K. Mashiter's
laboratory) and parathyroid hormone (PTH)
and calcitonin (CT).
Based on the results of the multiple
hormone measurements, the only hormones
which showed any promise as tumour
markers in bronchial carcinoma were CT
and PTH. CT was measured by a radio-
immunoassay described in detail elsewhere
(Coombes, et al., 1974). The normal levels
of CT are all below the detection limit of
this assay (0.1 ,ug/l). PTH was assayed by
a modification of the method described by
Greenberg et al. (1974) using a human PTH
standard. The normal range using this
assay is <0-1-0-73 ,ug/l. CT and PTH were
measured in 66 patients in the latter part
of the study, together with the CEA
measurements.
In a small number of cases, it waspossible
to carry out longitudinal studies for both
CEA and CT.
RESULTS
CEA
A total of 107 patients were studied.
In 29 cases only a single estimation of
the CEA content of the plasma was
made, and the results of these single
specimens and the first specimens from
those patients in whom series of estima-
tions were carried out before and after
treatment and at subsequent follow-up
are shown in Table I.
The normal level of plasma CEA has
been a matter of some uncertainty.
Laurence et al. (1972) found that a normal
control population between the ages of 30
and 40 years had a plasma CEA content
of less than 12-5 jug/l. An equivalent
level (2-5 ,ug/l) estimated by the Hoffmann
La Roche method was taken as normal
by Vincent and Chu (1973) in an extensive
study of CEA in bronchial carcinoma.
Using this level as the upper limit of
normal, a high proportion of cases (75%)
were found to have abnormal levels.
However, more recent studies have shown
that the level may be raised by smoking
or by other non-specific factors affecting
the patients' health (Hansen et al., 1974)
and these non-specific factors may be
the cause of the elevation in some cases
of bronchial carcinoma. The non-specific
causes are, however, unlikely to be the
cause of a level in excess of 40 ,ug/l
and this level should therefore be regarded
as definite evidence of a CEA-producing
tumour (Mackay et al., 1974).
The results obtained here and shown
in Tables I and II would support this
view. The largest group of patients has
CEA levels of between 10 and 30 ,ug/l
and many of these are probably raised
due to non-specific causes. It is likely
that these non-specific causes are infre-
quently responsible for a rise of above
30 ,tg/l in most patients, while true
CEA-producing tumours often cause rises
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TABLE I. CEA Levels in 107 Cases of Bronchial Carcinoma According to Histological
Type
CEA levels (ug/l)
Histological
type
Squamous (48)
Oat-cell (32)
Anaplastic (12)
Adeno (8)
Unkno-wn (7)
Total (107)
0-10-9
No. %
7 14-6
9 28-1
3 25-0
1 12-5
1 14-3
11-20 -9
No.
23 47 - 9
13 40- 6
4 3:3-3
1 12-5
4 57-1
21-30- 9
No. %
12 25-0
3 9-4
2 16-7
2 25-0
0)
:31 40- 9
No. %
3 6-3
1 3-1
0 0
1 12- 5
1 14-3
41+
No. %
3 6- 3
6 18-8
3 25 0
.3 37-5
1 14:-3
21 19-6 45 42-1 19 17-8 6 5-6 16 15-0
of well above 40 ~tgll, as shown in Table
II. Table I shows these results in full,
to demonstrate the differences in CEA
levels according to histological type, and
to enable comparisons with other series
in which other upper levels of normal
TABLE II. CEA Levels Above 40 ,ug/l
Squamous
88
97
152
Oat cell
50
59
67
273
790
800
Anaplastic
50
72
300
Adeno Unknown
75 270
92
131
TABLE III.-Initial and Highest Level
of Placsma CEA in Serial Estimations
(01g/1)
Initial
Histology level
Squamous 15 7
18-3
22
27 -5
30-5
35
36
36-5
Oat cell 5-4
10-6
10- 8
12-1
14-9
16 -4
24
Highest
level
105
42
270
49
47
340
42
45
43
76
300
81
1900
47-5
40-5
Anaplastic 12 640
Adeno 22 - 7 55
31 87
Unknowii 18 - 3 44
Interval between
estimations
(months)
20
7
6
0-5
0-5
12
4
5
2
6
7
1
1,3
12
5
4
6
4
12
were used (Laurence et al., 1972; Vincent
and Chu, 1-973).
Among the cases in which follow-up
CEA levels in the plasma were obtained,
it was found that in 19 the level rose
from a previously normal or non-specific-
ally raised value to a level above 40
jug/l, as shown in Table III. Four out
of the 6 cases in which the circulating
CEA was above 31 ,ug/l, 4/19 above 21
jug/l, 7/45 above 11 ,ug/land 3/21 below 10-9
jug/l, had levels above 40 ,tg/l in subse-
quent samples. These figures are good
evidence that a proportion of cases with
CEA levels of below 40 tg/l have CEA-
producing tumours which cause a raised
level with further growth or dissemination
of the neoplasm. Table IV shows the
number and percentage of cases in each
histological group in which a CEA level
above 40 pg/l was found either initially
or during follow-up.
CT and PTH
The results of the initial CT and PTH
assays are shown in Table V. A total
TABLE IV. Patients with CEA Levels
(Initial or Subsequent) of 40 utg/l or
More, According to Tumour Type
Nulmber
Histological type No. assayed >40 ug/l
Squamouis 48 11 22- 9
Oat cell 32 13 40-6
Anaplastic 12 4 33 0
Adeno 8 5 62- 5
UTiknowni 7 2 28- 6
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TABLE V. Pretreatment CT and PTH
CT PTH
No. assayed1 No. elevatedi No. assaye(d No. elevated
.30
28
4
2
2
13
21
3
1
1
43 -3
75-0
750(
50- 0
50-0
28
24
4
1
2
6
1
0
0
21 -4
4-2
25-0
0
0
Total 66 39 59- 1
of 559-I% of tumours had abnormal
levels of CT and 140% had elevated PTH
levels. The most striking finding is the
association of abnormal plasma CT levels
with oat-cell carcinomas. 75%0 of patients
with oat-cell carcinomas had increased
circulating CT, and 11 of these cases
had levels (up to 4-57 ,ug/l) in the range
normally associated with medullary thy-
roid carcinoma.
Longitudinal studies
Two instructive cases are shown in
Figs. 1 and 2. The first case only had
CEA measurements, the second had CEA
and CT measurements but only the CT
levels were abnormal. A third case in
which both markers were elevated is
described in more detail.
Fig. 1 shows the changes in CEA level
during treatment of a 56-year-old woman
presenting with an apparently localized
oat-cell carcinoma of the right upper-lobe
bronchus. She was treated by split-course
radiotherapy to a total dose of 5000 rad,
and the CEA level fell rapidly from 760
to 36 jug/l, and at this time there was no
clinical, X-ray, radioisotope or other
biochemical evidence of tumour. Broncho-
scopy showed apparent complete regres-
sion of the primary. Subsequently she
developed brain and later extradural
spinal deposits which were treated by
local radiotherapy with good response.
Her CEA level during this period rose
steadily, to a very high level before her
death. Autopsy showed widespread meta-
stases and regrowth ofthe primary.
Fig. 2 shows the CEA and CT levels
of a 54-year-old woman treated by
59
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Fic. 1. Plasma CEA levels (luring the
course of treatment in patient M.L. (oat-
cell carcinoma). The hatched areas repre-
sent: A, radiation to the primary tumour
in the chest; B, radiation to cerebral
metastases; C, radiation to lumbo-sacral
region for extradural metastases.
radiotherapy and combination chemo-
therapy for an oat-cell carcinoma of the
bronchus. The CEA levels in this patient
were normal in the beginning and re-
mained unchanged throughout. The CT
levels are of great interest; initially the
level was minimally elevated and there
was then a dramatic rise following
radiotherapy. During follow-up for almost
a year the CT levels remained undetect-
able, even shortly before her death from
brain metastases.
Fig. 3 shows the CEA and CT levels
Histological
type
Squamouis
Oat-cell
Adeno
Anaplastic
UJnknowu
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FIG. 2.-Plasma CEA (0 O) and cal-
citonin (0 0) levels during the course
of treatment in patient G.I. (oat-cell
carcinoma). The hatched areas represent:
A, radiation to the primary tumour in
the chest; B, radiation to cerebral meta-
stases. t : combination chemotherapy
(cyclophosphamide, methotrexate, CCNU).
in a 57-year-old woman with an oat-cell
carcinoma of the bronchus involving
local nodes and probably peribronchial
tissues. Radiotherapy was started for
the primary lesion (3000 rad in 10 frac-
tions) and 5 days later the patient was
complaining of nausea, vomiting and
painintheright shoulder, and onexamina-
tion jaundice and tender hepatomegaly
were noted. A liver scan was made and
intensive chemotherapy was begun, using
a combination of prednisone, 5-fluorour-
acil, cyclophosphamide and adriamycin
and followed up a week later with bleo-
mycin and vincristine. Symptomatic im-
provement ensued and the liver was noted
to be smaller. Radiotherapy was given
to the liver (200 rad, followed by 300 rad
one month later) and chemotherapy was
continued. A repeat liver scan confirmed
the diminution in the size of the whole
organ and of the cold areas noted on
the initial scan. Similarly the chest
X-ray showed almost complete resolution
of the opacity in the left lung. Both CEA
and CT levels were raised prior to treat-
ment, and showed a further increase
during her initial radiotherapy. Subse-
quently there was a marked fall in the
levels of both markers (Fig. 3) as a
result of chemotherapy. The patient died
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FIG. 3.-Plasma CEA (0 O) and cal-
citonin ( 0) levels during the
course of treatment in patient W.H. (oat-
cell carcinoma). The hatched areas repre-
sent: A, radiation to the primary tumour
in the chest; B, radiation to hepatic
metastases. t: combination chemotherapy
(see text).
unexpectedly 2 months after commencing
treatment. Post mortem examination re-
vealed that viable tumour tissue was
only present in the liver, where none of
the nodules was greater than 2-0 cm in
diameter.
DISCUSSION
The practical importance of any cir-
culating tumour marker depends on 3
main factors. Firstly, the frequency with
which the marker is found in any popula-
tion of tumour patients; secondly, a
good correlation between the marker
level and the mass oftumour; and thirdly,
the availability of an effective treatment
for the malignancy in question.
The importance of marker frequency
depends on the way in which it is intended
to use the information obtained. If it is
intended to use the marker as a screening
or diagnostic test, then it must be present
in virtually 100% of cases. In this con-
text, Concannon et al. (1974) concluded
that CEA is of no value in bronchial
carcinoma. Similarly, if the marker is
to be applied as a test for disseminated
disease, and thus exclude patients who
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are unsuitable for surgery, it must cor-
relate very closely with the presence
of metastases. Although CEA does not
meet these requirements, Vincent et at.
(1975) have presented good evidence to
show that the prognosis is very poor in
patients with significantly raised CEA
levels who undergo surgery. In this
series, 5/7 patients with initial CEA
levels above 15 ,ug/l (Hoffmann La Roche)
were dead in 5 months, and all were dead
within one year.
The correlation between the level of
tumour marker and the mass of tumour
depends on a number of factors. As
indicated in the results section, the CEA
levels tended to rise as the disease ad-
vanced. However, the plasma level at
any one time reflects a balance between
production and degradation and it is
impossible to say whether there is a
precise relationship between the CEA
(or CT) level and the tumour mass.
The fact that the CEA levels rose in an
exponential fashion in some patients
(Fig. 1) would suggest that some cor-
relation exists.
In several tumours it has been shown
that a suitable marker will detect the
presence of disseminated disease which
it is impossible to diagnose by other
methods. The most notable examples
are choriocarcinoma (Bagshawe, 1967;
Crawford, 1972) and testicular teratomas
in which the measurement of HCG/3 sub-
unit (Cochran et al., 1974; Keogh et
al., 1975) has been applied successfully to
treatment. Undoubtedly, CEA can detect
recurrence of colo-rectal cancer before it
becomes clinically apparent, but this
association has not had the same impact
because chemotherapy is not as effective
when these tumours disseminate.
It is possible to ascertain the value
of a tumour marker, only when there is
a sufficient variety of chemotherapeutic
agents and schedules available to permit
variations in treatment according to
changes in levels of circulating marker
substance. Previously, chemotherapy for
bronchial carcinoma has not been particu-
larly effective but, more recently, several
published series have shown that the
prognosis for oat-cell carcinomas may be
improved by the use of more radical
combinations ofradiotherapy and chemo-
therapy (Eagan et at., 1974; Johnson et
al., 1976; Choi and Carey, 1976; Hornback
et at., 1976). In the past this type of
carcinoma has carried a very poor prog-
nosis because the disease is almost always
disseminated at the time of diagnosis.
Nevertheless, oat-cell carcinomas can be
considered to have some advantages, in
thatthey are usually extremelyresponsive
to irradiation and also more responsive
to chemotherapy than other histological
types ofbronchial carcinoma. In addition,
theyproduce avariety oftumour markers.
The data presented here indicate that
knowledge of changes in tumour-marker
levels could influence the choice and
schedule of therapy and might effect
a more favourable outcome. Thus, the
case of oat-cell carcinoma of the right
upper-lobe bronchus illustrated in Fig. 1
showed a marked and rapid decrease in
the level of CEA with local radiotherapy.
For some considerable time after com-
pletion of treatment, there was no evi-
dence of disease other than the slightly
raised CEA level. The chest X-ray,
bronchoscopy and radioisotope bone scan
were all normal throughout the course
of the disease, until a few weeks before
the patient's death. The clinical evidence
of such an excellent local response would
suggest that the tumour was highly
radiosensitive. Given the known natural
history of oat-cell tumours, chemotherapy
would seem to offer the only hope of a
prolonged remission. In this case, if the
CEA level had been used as a guide to
treatment, chemotherapy would have
been instituted during the period of
apparent remission. Similarly, a rising
CEA (or other marker) level during one
chemotherapeutic regimen should prompt
a change to alternative drug combinations.
The cases in which both CEA and CT
were measured revealed some interesting
differences. The case of oat-cell carcinoma
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illustrated in Fig. 2 had normal CEA
levels throughout, whereas the CT level
was abnormal at the onset and showed
a dramatic rise with radiotherapy, pos-
sibly due to sudden release of stored
hormone from regressing tumour tissue.
In this patient, chemotherapy was insti-
tuted and the CT became undetectable
and remained so during follow-up for
almost one year. Thus, it would seem
that neither CEA nor CT had any poten-
tial as markers in this patient, despite
the fact that the tumour appeared to
be producing and storing CT. However,
it must be remembered that the CT
radioimmunoassay used in this study
does not detect levels of the hormone
circulating in normal individuals. The
use of a more sensitive assay (Hillyard et
al., 1977) in this patient might have
shown that the CT level was increasing,
yet remaining within the normal range,
as the disease progressed. In other cases,
as shown in Fig. 3, both CEA and CT were
elevated. In this patient with disseminated
oat-cell carcinoma, a treatment pro-
gramme was planned along the lines
suggested by Johnson et al. (1976). An
excellent clinical response was obtained,
and this was accompanied by a well
marked drop in the levels of CEA and
CT.
Clearly CEA and CT are not ideal
tumour markers for bronchial carcinoma,
but in an individual case where the level
ofone or other marker is elevated initially,
or subsequently rises to abnormal levels,
its measurement may prove a valuable
aid to therapy. Although the proportion
of cases in which this occurs is low, the
disease is common, and therefore CEA
and CT measurements are of potential
use in a large number of patients.
This would be of particular importance
in oat-cell tumours, in which CEA levels
are frequently elevated and CT levels are
abnormal in 75%0 of cases. Further
longitudinal studies are required in order
to define more precisely the role of these
tumour markers in the overall manage-
ment of bronchial carcinoma.
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